Most interesting, a new phase I study using SYHA1813, a VEGFR and CSF1R dual inhibitor, has been reported to show anti-tumor activity in patients with recurrent High-Grade Gliomas and Advanced Solid Tumors (170). Here, CSF1R is linked to neoplasm.